O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy.
AffiliationCancer Research UK Carcinogenesis Group, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.
MetadataShow full item record
AbstractINTRODUCTION: Alkylating agents are frequently used in the chemotherapy of many types of cancer. This group of drugs mediates cell death by damaging DNA and therefore, understandably, cellular DNA repair mechanisms can influence both their antitumour efficacy and their dose-limiting toxicities. SOURCES OF DATA: This review focuses on the mechanism of action of the DNA repair protein, O(6)-methylguanine-DNA methyltransferase (MGMT) and its exploitation in cancer therapy and reviews the current literature. AREAS OF AGREEMENT: MGMT can provide resistance to alkylating agents by DNA damage reversal. Inhibition of tumour MGMT by pseudosubstrates to overcome tumour resistance is under clinical evaluation. In addition, MGMT overexpression in haematopoietic stem cells has been shown in animal models to protect normal cells against the myelosuppressive effects of chemotherapy: this strategy has also entered clinical trials. AREAS OF CONTROVERSY: MGMT inhibitors enhance the myelotoxic effect of O(6)-alkylating drugs and therefore reduce the maximum-tolerated dose of these agents. Retroviral vectors used for chemoprotective gene therapy are associated with insertional mutagenesis and leukaemia development. GROWING POINTS: The results of ongoing preclinical and clinical research involving various aspects of MGMT modulation should provide new prospects for the treatment of glioma, melanoma and other cancer types. AREAS TIMELY FOR DEVELOPING RESEARCH: Tissue- and tumour-specific approaches to the modulation of MGMT together with other DNA repair functions and in combination with immuno- or radiotherapy are promising strategies to improve alkylating agent therapy.
CitationO6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. 2008, 85:17-33 Br. Med. Bull.
JournalBritish Medical Bulletin
- The specific role of O(6)-methylguanine-DNA methyltransferase inhibitors in cancer chemotherapy.
- Authors: Sun G, Zhao L, Zhong R, Peng Y
- Issue date: 2018 Aug 1
- Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
- Authors: Cai S, Xu Y, Cooper RJ, Ferkowicz MJ, Hartwell JR, Pollok KE, Kelley MR
- Issue date: 2005 Apr 15
- Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage.
- Authors: Paranjpe A, Zhang R, Ali-Osman F, Bobustuc GC, Srivenugopal KS
- Issue date: 2014 Mar
- Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant of O6-methylguanine-DNA-methyl transferase.
- Authors: Southgate TD, Garside E, Margison GP, Fairbairn LJ
- Issue date: 2006 Aug
- Temozolomide: mechanisms of action, repair and resistance.
- Authors: Zhang J, Stevens MF, Bradshaw TD
- Issue date: 2012 Jan